Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations

Annals of Neurology
L J ThalR Katzman

Abstract

Six patients with myoclonus of varying cause were treated with L-5-hydroxytryptophan (L-5-HTP) and carbidopa. While spontaneous myoclonus decreased in three of the patients and action myoclonus in four, only two patients had marked functional improvement. Side effects included gastrointestinal and affective disturbances. L-5-HTP therapy caused a diminished frequency of paroxysmal discharges in the electroencephalograms of three patients which did not always correlate with clinical improvement. Lumbar cerebrospinal fluid 5-hydroxyindoleacetic acid (5-HIAA) concentration after probenecid was decreased in all patients prior to therapy, but this reduction did not predict treatment response. Urinary excretion patterns for 5-HTP, serotonin, and 5-HIAA during treatment were similar in responders and nonresponders. It is concluded that while some patients with myoclonus do benefit from L-5-HTP therapy, biochemical and electrophysiological tests are not useful predictors of treatment response, and the high incidence of side effects limits the usefulness of this therapy.

References

Sep 6, 1975·Lancet·D ChadwickC D Marsden
Mar 1, 1978·Annals of Neurology·I RapinJ S O'Brien
Apr 1, 1978·Acta Neurologica Scandinavica·I MagnussenB de Fine Olivarius
Jan 13, 1977·The New England Journal of Medicine·M H Van WoertM B Bowers
Dec 21, 1977·Biochemical and Biophysical Research Communications·J S O'Brien
Jan 1, 1976·Neurology·M A Goldberb, J D Dorman
Apr 1, 1973·Journal of the Neurological Sciences·C GuilleminaultD Cousin
Mar 1, 1972·Clinica Chimica Acta; International Journal of Clinical Chemistry·N S SharplessC A Owen
Mar 1, 1963·Brain : a Journal of Neurology·J W LANCE, R D ADAMS

❮ Previous
Next ❯

Citations

Sep 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·R R MatsumotoD D Truong
Nov 30, 2000·Current Treatment Options in Neurology·S Frucht
Jun 27, 2008·Current Treatment Options in Neurology·Victoria C Chang, Steven J Frucht
Apr 1, 1995·Pharmacology, Biochemistry, and Behavior·R R MatsumotoD D Truong
Jul 3, 1998·European Journal of Pharmacology·E J PappertP M Carvey
Jul 1, 1996·Mayo Clinic Proceedings·J N Caviness
Sep 5, 2001·Neurologic Clinics·K Blindauer
Dec 1, 1985·Journal of Neurology, Neurosurgery, and Psychiatry·J A ObesoJ M Martínez Lage
Oct 1, 1985·The Journal of Clinical Investigation·Y ShenkerR J Grekin
Jan 1, 1985·Annals of the New York Academy of Sciences·L J Thal
Jan 1, 1983·International Journal of Psychiatry in Medicine·R L Goldberg
Jan 1, 1986·Suicide & Life-threatening Behavior·H M van Praag
Jun 30, 2018·Current Neuropharmacology·Faheem Hyder PottooMohammad Azam Ansari

❮ Previous
Next ❯

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.